Caredx, Inc Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2017
January 08, 2018 at 08:30 am
Share
CareDx Inc. provided preliminary revenue guidance for the fourth quarter and full year ended December 31, 2017. For the quarter, the company expected revenue to be between $12.3 million and $12.5 million, an increase of 13%-15% compared with $10.9 million in the fourth quarter of 2016.
For the full year, the company expected revenue to be between $48.1 million and $48.3 million, an increase of 18%-19% compared with $40.6 million in 2016.
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The Company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The Companyâs product portfolio includes AlloSeq Tx, QTYPE, Olerup SSP, AlloSeq HCT and AlloSeq cfDNA. It develops and provides diagnostic surveillance testing services for various transplant recipients.
CAREDX, INC 
